Celldex Therapeutics (CLDX) Competitors $24.61 -1.31 (-5.05%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$24.78 +0.17 (+0.69%) As of 09/19/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX vs. ALKS, LGND, FOLD, BCRX, MNKD, INVA, NVAX, DVAX, OPK, and GERNShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals MannKind Innoviva Novavax Dynavax Technologies OPKO Health Geron Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Which has more volatility & risk, ALKS or CLDX? Alkermes has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Do analysts rate ALKS or CLDX? Alkermes currently has a consensus price target of $41.85, suggesting a potential upside of 50.58%. Celldex Therapeutics has a consensus price target of $46.67, suggesting a potential upside of 89.62%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has higher earnings and valuation, ALKS or CLDX? Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B2.95$367.07M$2.0813.36Celldex Therapeutics$7.02M232.81-$157.86M-$3.01-8.18 Is ALKS or CLDX more profitable? Alkermes has a net margin of 23.15% compared to Celldex Therapeutics' net margin of -3,446.88%. Alkermes' return on equity of 24.86% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Celldex Therapeutics -3,446.88%-27.61%-26.20% Do institutionals & insiders believe in ALKS or CLDX? 95.2% of Alkermes shares are held by institutional investors. 4.4% of Alkermes shares are held by company insiders. Comparatively, 4.4% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor ALKS or CLDX? In the previous week, Celldex Therapeutics had 1 more articles in the media than Alkermes. MarketBeat recorded 7 mentions for Celldex Therapeutics and 6 mentions for Alkermes. Alkermes' average media sentiment score of 1.44 beat Celldex Therapeutics' score of 0.71 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats Celldex Therapeutics on 12 of the 16 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.72B$3.15B$5.80B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-8.1821.0580.5826.78Price / Sales232.81450.04534.44123.53Price / CashN/A46.6037.9961.55Price / Book2.199.6615.776.40Net Income-$157.86M-$53.22M$3.30B$271.80M7 Day Performance0.65%3.11%5.36%3.49%1 Month Performance17.81%7.56%8.10%9.90%1 Year Performance-40.32%11.15%81.36%28.62% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics2.1605 of 5 stars$24.61-5.1%$46.67+89.6%-40.2%$1.72B$7.02M-8.18150Positive NewsAnalyst ForecastALKSAlkermes4.5989 of 5 stars$28.45-5.0%$41.31+45.2%-2.0%$4.94B$1.56B13.681,800Positive NewsHigh Trading VolumeLGNDLigand Pharmaceuticals4.2396 of 5 stars$165.86-0.5%$176.50+6.4%+58.6%$3.27B$187.58M-41.4780News CoveragePositive NewsFOLDAmicus Therapeutics3.9449 of 5 stars$7.98-0.1%$16.00+100.5%-24.3%$2.46B$571.16M-66.49480News CoverageAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.266 of 5 stars$8.19-1.0%$16.70+103.9%-5.5%$1.74B$450.71M-45.50530Positive NewsMNKDMannKind4.2792 of 5 stars$5.57+0.5%$10.71+92.4%-19.0%$1.70B$285.50M50.64400Analyst ForecastInsider TradeShort Interest ↓INVAInnoviva4.8043 of 5 stars$20.46-0.1%$42.75+108.9%-2.4%$1.29B$358.71M66.00100Positive NewsShort Interest ↓NVAXNovavax4.2141 of 5 stars$7.73-2.2%$14.29+84.8%-30.4%$1.28B$1.08B3.391,990DVAXDynavax Technologies4.2913 of 5 stars$9.70-3.6%$24.33+150.9%-15.7%$1.18B$316.27M-21.09350Positive NewsOPKOPKO Health4.3528 of 5 stars$1.42+5.2%$2.75+93.7%-8.8%$1.07B$713.10M-5.682,997GERNGeron3.0195 of 5 stars$1.37-2.1%$4.19+205.7%-72.2%$893.22M$164.45M-10.5470Positive News Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives MannKind Alternatives Innoviva Alternatives Novavax Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLDX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts